Merck's Pipeline Transformation Exceeds $70 Billion by Mid-2030s
Pharmaceutical giant Merck continues to diversify its portfolio and advance its pipeline of newer medicines, which is expected to exceed $70 billion in annual sales by the mid-2030s. This estimate comes from the company's Q2 presentation, which shows a clinically derisked pipeline spanning various products and programs.
The quarter saw several important milestones for Merck, including additional approvals for KEYTRUDA and KEYTRUDA QLEX, positive topline results for sacituzumab tirumotecan in endometrial cancer patients, and FDA approval for LIPFENDRA, the first oral PCSK9 inhibitor. The company is also advancing fixed-dose combinations with rosuvastatin and its Lp(a) program, MK-7262.
Merck's Q2 sales reached $16.6 billion, a 5% increase on a reported basis and 4% excluding foreign exchange. The company highlighted strength in Oncology and Animal Health, as well as contributions from newer launches. However, the quarter also saw GAAP operating expenses increase to $12.6 billion due to a $5.7 billion charge associated with Merck's acquisition of Terns.
The collaboration between Merck and Gilead on islatravir/lenacapavir in HIV treatment has yielded positive Phase 3 results, which could lead to a potential first once-weekly oral treatment option. Merck is also advancing this regimen along with ulonivirine toward Phase 3 development.